Emerald Medical Applications Corp. — Form 10-Q Summary
Period: Three months ended March 31, 2017. The filing identifies the registrant as Emerald Medical Applications Corp., not QUANTUM X LABS INC.; confirm that this is the intended filing.
Business context
Emerald is a development-stage digital health company developing and commercializing DermaCompare, software for skin imaging and lesion analysis. Its stated sales strategy includes licensing the product to healthcare providers and organizations, directly and through distributors and channel partners. The company reported no revenue in either quarter compared.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $178,887 | $103,348 |
| General and administrative | $158,165 | $1,799,520 |
| Operating loss | $(337,052) | $(1,902,868) |
| Finance expense (income) | $(220,835) | $2,638 |
| Net loss | $(557,887) | $(1,900,230) |
| Basic and diluted loss per share | $(0.03) | $(0.11) |
| Net cash used in operations | $(406,160) | $(173,002) |
Gross and operating margins are not meaningful because the company had no revenue. The lower year-over-year net loss mainly reflects substantially lower G&A, which management attributes to merger-related costs and share-based compensation in Q1 2016. R&D and finance expense increased.
At March 31, 2017, cash and cash equivalents were $122,992, restricted cash was $12,618, current assets were $134,512, and total assets were $176,299. Current and total liabilities were $1,049,950, including $593,338 of current convertible notes and $47,468 of accrued interest. Stockholders’ deficit was $873,651. Cash rose from $4,486 at year-end, primarily because the company received $526,213 from common-stock issuance; investing activities used $1,547.
Changes, outlook, and risks
- On February 24, 2017, the company issued 1,315,563 restricted shares to Publicis 90 at $0.40 per share, in connection with a previously awarded €500,000 prize. The cash flow statement reports $526,213 in net equity proceeds.
- Convertible notes of $155,000 came due in March 2017, with the remaining balance due in June 2017. Management said it was discussing extensions and believed they would be successful; the filing does not report a completed extension.
- Management said the company may need up to an additional $1.5 million over the next 12 months to implement its business plan and fund operations. It cautioned that additional financing is necessary to continue as a going concern and that limited resources may impede borrowing or fundraising.
- Israeli Chief Scientist grants totaled approximately $222,000. Royalties of 3.5% of sales, capped at the grant amount, are contingent on successful project outcomes and product sales.
- Disclosure controls and procedures were reported ineffective as of March 31, 2017. The filing reports no material changes in internal control over financial reporting during the quarter and no legal proceedings.
- The interim financial statements are unaudited. Although the MD&A refers to an auditors’ going-concern opinion for the period, the filing does not clearly reconcile that statement with the unaudited interim presentation.
Important facts to verify
- Confirm the issuer identity: the supplied filing is for Emerald Medical Applications Corp., whereas the request names QUANTUM X LABS INC.
- Check the cash flow statement’s comparative-period headings: both columns are labeled as ended March 31, 2017, although the statements and discussion present a 2017-versus-2016 comparison.
- Reconcile the reported negative working capital of $873,651 with the balance-sheet figures: current liabilities of $1,049,950 less current assets of $134,512 imply a deficit of $915,438.
- Verify the status and terms of the overdue and upcoming convertible-note maturities, and whether the company obtained the additional financing it said it might need.
- Confirm share-count disclosures: the balance sheet reports 21,247,041 shares at March 31, 2017, while the cover page gives a different share count and a date of May 22, 2016.